Stenocare A/S ("Stenocare"), a European supplier of prescription-based medical cannabis products, today announces a strategic partnership with WEECO Pharma GmbH ("WEECO"), a German pharmaceutical company specializing in cannabinoid-based medicines. This collaboration marks the official launch of WEECO ASTRUM Oil products in Germany-one of Europe's most advanced and rapidly growing medical cannabis markets.

The first product to be introduced under the partnership, WEECO ASTRUM 10-10 extract, will be available to patients beginning February 2026. The product is based on Stenocare's proprietary ASTRUM oil technology and has been approved for sale by the German health authorities.

Combining Strengths for Growth in Germany
The partnership brings together the complementary capabilities of two established industry players:

• Stenocare contributes pharmaceutical-grade, prescription-based medical cannabis oils developed under EU-GMP standards. With a proven track record for quality and patient safety, Stenocare continues to expand its footprint across Europe through strong and trusted partnerships.
• WEECO brings industry-leading expertise in regulatory compliance, pharmaceutical consulting, sales and distribution, and medical cannabis product registration in Germany and abroad.

Together, the collaboration forms a powerful platform for long-term growth in the German medical cannabis market.

Rolf Steno, CCO of Stenocare A/S, commented:
"Germany represents one of the most important markets for medical cannabis in Europe, and we are proud to partner with WEECO. This partnership ensures that the WEECO ASTRUM Oil products can reach patients through a trusted and well-established distribution channel, while maintaining our commitment to safety, quality, and patient care."

Tony Schröter, Managing Director of WEECO Pharma GmbH, added:
"We are delighted to collaborate with Stenocare to bring their premium and highly innovative ASTRUM Oil products to German patients. With our regulatory experience and established partnerships, we can ensure a smooth introduction of these products into pharmacies and medical practice networks across Germany and selected international markets."

Introducing A New Next-Generation Medical Cannabis Oil
The initially fully registered product, WEECO ASTRUM 10-10 extract, contains 10 mg/ml THC and 10 mg/ml CBD in a 30 ml bottle, providing a balanced formulation well suited for a broad range of patient needs in Germany. Since 2019, Stenocare has invested significantly in developing and testing next-generation medical cannabis oil products to strengthen its position as a leader in prescription-based medical cannabis. The ASTRUM line is the result of this development effort and uses patented oil technology for which Stenocare holds worldwide exclusivity.

Innovative Technology to improve Bioavailability
The WEECO ASTRUM 10-10 extract features an innovative oil technology designed to enhance the bioavailability of cannabinoids in the bloodstream and will also serve as the first water-soluble application method available for German patients. This addresses a well-known challenge in medical cannabis treatment: ensuring consistent dosing and predictable absorption of active ingredients. By supporting more reliable uptake, the ASTRUM technology has the potential to improve treatment consistency and contribute to better patient outcomes.

Sign-up for Stenocare news here: https://stenocare.com/subscribe-for-newsletter/ to automatically receive the latest news and information about the company.